National Institute for Health and Care Excellence (NICE)
- Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer.
- Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation.
- Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer.
.png)
No hay comentarios:
Publicar un comentario